Education
About Us
Working with TipRanks
Follow Us
Embecta Corporation (EMBC)
:EMBC
EMBC Stock Chart & Stats
$13.67
$0.16(0.83%)
At close: 4:00 PM EST
$13.67
$0.16(0.83%)
Day’s Range― - ―
52-Week Range$9.20 - $21.23
Previous CloseN/A
Volume119.84K
Average Volume (3M)359.73K
Market Cap
$856.22M
Enterprise ValueN/A
Total Cash (Recent Filing)$225.50M
Total Debt (Recent Filing)$1.43B
Price to Earnings (P/E)10.2
Beta0.99
Next Earnings
Feb 06, 2026EPS Estimate
0.67Last Dividend Ex-Date
Dec 05, 2025Dividend Yield5.2%
Share Statistics
EPS (TTM)0.50
Shares Outstanding58,485,120
10 Day Avg. Volume430,768
30 Day Avg. Volume359,726
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$25.00Price Target Upside82.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Brand Transition And Pipeline InitiativesThe company is nearly done with its brand transition in the U.S. and Canada, and is progressing on pipeline initiatives such as pen needles for generic GLP-1 administration.
Debt Reduction And Cost SavingsEMBC expects to reduce its debt by $150M this fiscal year while simultaneously driving $7M-$8M in pre-tax cost savings in the second half of the fiscal year.
Growth In Emerging MarketsEmerging markets continue to be a source of growth as EMBC plans to introduce products to meet local market needs in new regions.
Bears Say
Chinese Market ConcernsEMBC expressed near-term concern about the Chinese market, where distributors have reported customers buying more local Chinese brands as a result of tariffs and recent geopolitical tensions.
Revenue Decrease ExpectationThe full-year guide implies a ~$30M sequential decrease in revenue for F4Q at the midpoint, reflecting the reversal of the benefits from timing of distributor orders and stocking in F3Q, in addition to rebate reserve adjustments.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $9.20 and its highest was $21.23 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $856.22M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is Feb 06, 2026 which is in 56 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on Nov 25, 2025. The company reported $0.5 earnings per share for the quarter, beating the consensus estimate of $0.455 by $0.045.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Undervalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.15 which represents an annual dividend yield of 5.2%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.67.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 58,485,120 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $0.5 in its last earnings report, beating expectations of $0.455. Following the earnings report the stock price went down -7.266%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
Embecta Corporation Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (82.88% Upside)
$25.00 (82.88% Upside)
Blogger Sentiment
Bullish
EMBC Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 424.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 17.5%
Last 30 Days ▲ 13.7%
Last 30 Days ▲ 13.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.69%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corporation (EMBC) is a global leader in diabetes care, specializing in the design, manufacturing, and distribution of insulin delivery devices and other diabetes management solutions. The company focuses primarily on the production of insulin syringes, pen needles, and infusion sets aimed at enhancing the quality of life for people living with diabetes. With a commitment to innovation and patient-centric solutions, Embecta operates in the healthcare sector, providing essential products that facilitate effective diabetes management.
EMBC Company Deck
EMBC Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Embecta's fiscal year 2025 performance showed strong strategic advancements and financial discipline, particularly with the implementation of a new ERP system, GLP-1 strategy progress, and significant debt reduction. However, these were countered by revenue declines across key markets, particularly in the US and China, alongside increased cannula costs impacting margins.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$25.00
▲(82.88% Upside)
Technical Analysis
Dynavax
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
2.22% Insiders
25.03% Mutual Funds
29.34% Other Institutional Investors
18.76% Public Companies and
Individual Investors